Highest-materiality recent filing
VivoSim gets Nasdaq delisting notice for bid price; proposes 1:5-1:20 reverse split
Nasdaq notice on Aug 17, 2026: VIVS closing bid below $1 for 30 consecutive sessions.
VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027
Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.
VivoSim Labs sets Sept 30, 2026 annual meeting; Aug 13 record date; Aug 9 deadline for proposals
Annual Meeting set for September 30, 2026; record date August 13, 2026.
VivoSim Labs receives Nasdaq delisting notice; subsequent transactions restore equity above $2.5M
Received Nasdaq delisting notice on July 20, 2026 for failing to maintain $2.5M minimum stockholders' equity; equity was $(1,099,000) as of March 31, 2026.
VivoSim prices $4.0M private placement of common stock and warrants at $0.85 per unit
Gross proceeds of ~$4.0M from sale of 4,705,883 shares (or pre-funded warrants) and warrants to purchase 4,705,883 shares at combined price of $0.85.
VivoSim prices up to $4M public offering, closes initial $3M tranche
Initial closing raised $3M at $1.14/share; 286,557 shares + 2,345,022 pre-funded warrants sold.
VivoSim Labs announces results of 2025 annual meeting; elects directors and ratifies auditor
Douglas Jay Cohen and David Gobel elected as Class II directors with 212,079 and 212,420 votes For, respectively.
VivoSim Labs appoints Tony Lialin as Chief Commercial Officer
Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
VivoSim Labs regains compliance with Nasdaq minimum equity and bid price rules
On April 30, 2025, Nasdaq confirmed VivoSim Labs demonstrated compliance with minimum $2.5M stockholders' equity and $1.00 bid price requirements.
Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
Organovo rebrands as VivoSim Labs, ticker changes to VIVS effective April 24
Company to carry forward 3D bioprinting and legacy technology as VivoSim Labs, Inc.
Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements
Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.
Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026
FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones
Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
Organovo implements 1-for-12 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split at ratio 1-for-12, effective March 20, 2025, to combine every 12 shares into 1.
Organovo announces 1-for-12 reverse stock split effective March 20, 2025 to regain Nasdaq compliance
1-for-12 reverse stock split effective 5:00 p.m. ET on March 20, 2025; adjusted trading begins March 21.
Organovo issues ~3M shares via warrant exercises and ATM sales, raising ~$2.3M
Issued 2,967,144 shares of common stock from warrant exercises and at-the-market sales.
Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting
Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.
Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement
Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.
Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase
Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.
Organovo grants Chairman Murphy options on ~1M shares at $0.5368, vesting over 3 years
Time-based option for 574,923 shares vests 1/3 annually over 3 years subject to continued service.
Organovo received Nasdaq delisting notice for bid price below $1 per share
Nasdaq notice on July 18, 2024: closing bid price below $1 for 30 consecutive business days.
Organovo prices $5.25M public offering of common stock and warrants
Offering of 6.56M units at $0.80/unit; gross proceeds $5.25M before expenses.
Organovo furnishes May 2024 corporate presentation; no specific financial data disclosed
Company posted investor presentation on its website covering business overview and strategy.
Organovo issues 1.35M shares for ~$1.8M under ATM facility
Issued 1,349,778 shares between Feb 1 and Apr 19, 2024; gross proceeds of $1.8 million.
Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis
FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.
Organovo issues ~967K shares via ATM and consultant grant; total outstanding 9.8M
Issued 65,789 shares to a consultant as compensation for marketing services under Rule 506(b) exempt transaction.
Organovo shareholders approve 2023 ESPP but reject officer exculpation amendment
2023 ESPP approved with 91.11% of votes cast; reserves 45,000 shares; effective October 31, 2023.
Organovo cuts 24% of workforce; estimates $0.5M severance costs, $1.5M annual savings
Workforce reduction of ~6 employees (24% of staff) effective August 25, 2023.
Organovo terminates General Counsel Tom Jurgensen; $345,000 severance
Tom Jurgensen, General Counsel and Corporate Secretary, terminated Aug 25, 2023 as part of reduction in force.
Organovo appoints Rosenberg Rich Baker Berman as new auditor effective Aug 31, 2023
Former auditor MHM ceased on Aug 10, 2023 after filing Q1 FY2024 10-Q.
Organovo reduces workforce by 24% and terminates General Counsel and CSO to focus on FXR314
Workforce reduced by ~6 employees (~24% of staff) effective Aug 25, 2023 to focus on clinical drug FXR314.
Mayer Hoffman McCann declines re-election as Organovo's auditor; no disagreements cited
MHM will not stand for re-election as auditor for FY ending March 31, 2024; effective by Q1 FY2024 10-Q filing or Aug 21, 2023.
Organovo acquires Metacrine's FXR program for $4M cash
Total cash consideration of $4M; $2M paid at closing and $2M due after transfer of program.
Organovo shareholders approve 2022 equity plan; Cohen and Gobel elected directors
Stockholders approved 2022 Equity Incentive Plan with 94.35% of votes cast; 1,236,738 shares reserved.
Organovo postpones 2022 annual meeting to Oct 12 due to low proxy turnout
Annual meeting moved from Sept 7 to Oct 12, 2022; new record date Sept 7.
Organovo appoints Vaidehi Joshi to Board of Directors as Class I Director
Appointment effective March 8, 2022; term expires at 2024 annual meeting.
Organovo settles patent disputes with BICO; receives $1.5M upfront and ongoing royalties
BICO will pay Organovo $1.5M upfront plus ongoing low-to-high single-digit % royalties on net sales of licensed products.
Organovo expands San Diego lease by 2,892 sq ft; lease commences Nov 29, 2021
Adds 2,892 rentable sq ft (Suite 202) at 11555 Sorrento Valley Road, San Diego; total Premises now 10,943 sq ft.
Organovo CFO Jonathan Lieber resigns; Thomas P. Hess appointed as President and CFO
Jonathan Lieber resigned effective Oct 6, 2021, to pursue a full-time opportunity; no disagreement with the Company.
Organovo reduces stockholder quorum from majority to one-third
Board approved amendment to Section 2.6 of Bylaws reducing quorum from majority to one-third of outstanding voting stock.
Organovo adjourns annual meeting to Oct 5 due to lack of quorum; only 45.6% voted
Annual meeting convened Sept 14, 2021 but adjourned with no business because only 45.6% of shares were voted.
On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.
Jeffrey Miner, Ph.D., the Company’s former Chief Scientific Officer, was notified that his employment with the Company would be terminated. Dr. Miner’s last day of employment was August 25, 2023.
Tom Jurgensen, the former General Counsel and Corporate Secretary of the Company, was notified that his employment with the Company would be terminated.
on August 16, 2023, Tom Jurgensen, the Company’s General Counsel and Corporate Secretary, and Jeffrey Miner, the Company’s Chief Scientific Officer, were each notified that his employment with the Company would be terminated.
on August 16, 2023, Tom Jurgensen, the Company’s General Counsel and Corporate Secretary, and Jeffrey Miner, the Company’s Chief Scientific Officer, were each notified that his employment with the Company would be terminated.
Effective March 8, 2022, the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”) appointed Vaidehi Joshi to the Board as Class I Director.
On October 6, 2021, the Company’s Board of Directors appointed Thomas P. Hess, age 57, as the Company’s newly appointed President, Chief Financial Officer and Principal Financial Officer, effective October 6, 2021, in connection with the resignation of Mr. Lieber.
On October 6, 2021, Jonathan Lieber, the President, Chief Financial Officer and Principal Financial Officer of Organovo Holdings, Inc. (the “Company”), notified the Company of his intent to resign, effective October 6, 2021, from his part-time role to pursue a full-time opportunity.
Max materiality 0.80 · Median 0.55 · Most common event other_material